11
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation

      guideline

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms (NEN) concerning follow-up and documentation are considered in this review. The documentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1. However, it should be stressed that evidence-based studies for follow-up are largely missing.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          978-3-318-06158-1
          978-3-318-06159-8
          0028-3835
          1423-0194
          2017
          September 2017
          17 February 2017
          : 105
          : 3
          : 310-319
          Affiliations
          aDepartments of Surgery and Clinical Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; bDepartment of Medical Oncology, Vall d'Hebron University Hospital, Vall Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; cDepartment of Visceral, Thoracic and Vascular Surgery, Philipps University, Marburg, Germany; dService de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Villejuif, France; eDepartment of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden; fDepartment of General, Digestive and Endocrine Surgery, R. Debré University Hospital, Reims, France; gDepartment of Endocrinology, Medical University of Silesia, Katowice, Poland; hSection of Endocrine Surgery, Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria; iDepartment of Surgery, Academic Medical Center, Amsterdam, The Netherlands; jNational Centre for Neuroendocrine Tumours, St. Vincent's University Hospital and Department of Clinical Medicine, St. James Hospital and Trinity College, Dublin, Ireland; kDepartment of General, Visceral and Transplant Surgery, Charité Universitätsmedizin Berlin, Berlin, Germany; lBeatson Oncology Centre, Gartnavel General Hospital, Glasgow, UK; mDepartment of Radiology and Molecular Imaging, Uppsala University Hospital, Uppsala, Sweden; nService de Radiologie, Hôspital Beaujon, Clichy, France
          Author notes
          *Ulrich Knigge, Departments of Surgery C and Clinical Endocrinology PE, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen Ø (Denmark), E-Mail ulrich.peter.knigge@regionh.dk
          Article
          458155 Neuroendocrinology 2017;105:310-319
          10.1159/000458155
          28222443
          f0b45772-731e-4aea-8651-605ed5cb9818
          © 2017 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 08 November 2016
          : 24 January 2017
          Page count
          Figures: 1, Tables: 2, References: 43, Pages: 10
          Categories
          Conference Report

          Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
          Chromogranin A,NT-pro-brain natriuretic peptide,TNM staging,Functional imaging,Follow-up,Neuroendocrine neoplasm,Neuroendocrine carcinoma,Somatostatin receptor imaging,Neuron-specific enolase,5-Hydroxyindoleacetic acid,Neuroendocrine tumor

          Comments

          Comment on this article